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Research
Air pollutant concentrations in many homes 
exceed health-based standards for chronic and 
acute exposures (Logue et al. 2011). On aver-
age, Americans spend > 65% of their time in 
residences (Klepeis et al. 2001), and numer-
ous studies have noted the importance of 
the indoor environment to cumulative air 
pollutant intake (Samet 1993; Weisel et al. 
2005). Impact assessment methods have been 
applied to estimate aggregate chronic health 
impacts for outdoor air pollution [Muller 
and Mendelsohn 2007; U.S. Environmental 
Protection Agency (EPA) 1999] and from 
pollutant inhalation in office buildings (Fisk 
et al. 2011). Yet, to our knowledge, no study 
has yet considered both disease incidence and 
severity to assess aggregate health impacts of 
air pollutant inhalation in residences.
Air pollutants known to be hazard-
ous based on epidemiological and toxico-
logical information include the “criteria 
pollutants” specified in the 1970 Clean Air Act 
Amendments (CAAA 1970) and hazardous 
air pollutants (HAPs) specified in the 1990 
CAAA (1990). In addition, concern is grow-
ing that some bioaccumulating semivolatile 
organic compounds and ultrafine particles—
both ubiquitously present in residences—may 
cause substantial adverse health effects at typi-
cal environmental levels. However, the current 
toxicological data is insufficient to quantify 
that impact. The U.S. EPA and the California 
EPA (CalEPA) each publish health standards 
or guidelines for long-term exposure concen-
trations to protect against cancer and non-
cancer chronic effects. The hazard associated 
with residential air pollutant exposure can be 
quantified as the percentage of homes that 
exceed specified non  cancer standards or as the 
incremental risk of cancer incidence across 
the population. These methods consider only 
disease potential for non  cancer end points 
and disease incidence for cancer; they do not 
incorporate disease severity. Quantitatively 
comparing the effects of individual residential 
indoor air pollutants (IAPs) and comparing 
their estimated cumulative health impact with 
that of other environmental hazards requires a 
single metric that includes both disease inci-
dence and severity. A comprehensive met-
ric will facilitate the evaluation of residential 
indoor air quality (IAQ) interventions, includ-
ing source control measures and ventilation.
Epidemiological and toxicological research 
has contributed to the development of 
tools to bridge the gap from measured pol-
lutant exposure levels to disease incidence, 
and from disease incidence to health costs in 
disability-adjusted life-years (DALYs) lost. 
Concentration–response (C-R) relationships 
have been quantified for criteria pollutants. 
The U.S. EPA aggregated several of these 
disease incidence models for use in the cost-
benefit analysis of the Clean Air Act (U.S. 
EPA 1999). Several studies have estimated the 
health impact per incidence of specific diseases 
(Hong et al. 2010; Lvovsky et al. 2000; Melse 
et al. 2010). Huijbregts et al. (2005) pub-
lished cumulative impact and effect factors for 
exposure to air pollutants, including air toxics 
and ozone. These models provide the basis for 
performing a human health impact assessment 
for inhalation of IAPs.
In this study we combined disease inci-
dence and DALY-based health impact models 
to develop a methodology for estimating the 
population-average health costs due to chronic 
inhalation of a broad suite of air pollutants in 
U.S. residences. We first analyzed published 
data to calculate mean exposure concentra-
tions and estimated age-dependent inhalation 
intakes. We used disease incidence and disease 
impact models to predict pollutant-specific 
impacts and total DALY-based health costs to 
identify the residential IAPs that have the great-
est impact on health in the United States. As a 
check on the method, and the estimated aggre-
gate impact of IAP, we compared our findings 
with independent estimates of DALY losses 
related to secondhand smoke (SHS) to diseases 
that could potentially result from air pollutant 
exposure and to all non  communicable, non-
psychiatric diseases in the United States.
Methods
IAP intake. To calculate pollutant inhalation 
in U.S. residences, we used a data compilation 
described by Logue et al. (2011) that includes 
summary statistics from 77 studies report-
ing residential air pollutant concentration 
measurements in the United States and other 
countries with similar lifestyles. The aggregate 
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Ba c k g r o u n d: Indoor air pollutants (IAPs) cause multiple health impacts. Prioritizing mitigation 
options that differentially affect individual pollutants and comparing IAPs with other   environmental 
health hazards require a common metric of harm.
oBjectives: Our objective was to demonstrate a methodology to quantify and compare health 
impacts from IAPs. The methodology is needed to assess population health impacts of large-scale 
initiatives—including energy efficiency upgrades and ventilation standards—that affect indoor air 
quality (IAQ).
Me t h o d s : Available disease incidence and disease impact models for specific pollutant–disease 
combinations were synthesized with data on measured concentrations to estimate the chronic heath 
impact, in disability-adjusted life-years (DALYs) lost, due to inhalation of a subset of IAPs in U.S. 
residences. Model results were compared with independent estimates of DALYs lost due to disease.
re s u l t s: Particulate matter ≤ 2.5 μm in aerodynamic diameter (PM2.5), acrolein, and formaldehyde 
accounted for the vast majority of DALY losses caused by IAPs considered in this analysis, with 
impacts on par or greater than estimates for secondhand tobacco smoke and radon. Confidence inter-
vals of DALYs lost derived from epidemiology-based response functions are tighter than those derived 
from toxicology-based, interspecies extrapolations. Statistics on disease incidence in the United States 
indicate that the upper-bound confidence interval for aggregate IAP harm is implausibly high.
co n c l u s i o n s: The approach demonstrated in this study may be used to assess regional and national 
initiatives that affect IAQ at the population level. Cumulative health impacts from inhalation in 
U.S. residences of the IAPs assessed in this study are estimated at 400–1,100 DALYs lost annually 
per 100,000 persons.
key w o r d s : air toxics, criteria pollutants, DALYs, exposure, impact assessment, indoor air pollut-
ants, indoor air quality. Environ Health Perspect 120:216–222 (2012).  http://dx.doi.org/10.1289/
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data were used to calculate concentrations rele-
vant to assessing chronic residential exposures 
to 267 chemical air pollutants. Seventy of the 
pollutants had sufficient toxicological and epi-
demiological data to calculate chronic health 
impact using the methodology described below 
and were included in this study (Table 1). Our 
analysis did not extend to contaminants from 
biological sources such as molds and allergens. 
We thus refer to the suite of pollutants consid-
ered as “non  biological.”
Determining annual population health 
impact. The annual health impact of residential 
IAPs was calculated by considering the total 
intake in residences as an increment adding 
to intake in other environments. The incre-
ment was calculated by considering in-home 
inhalation of air containing the population-
mean exposure concentrations relative to the 
theoreti  cal case of the population inhaling resi-
dential air containing no pollutants.
The DALY metric allows quantification 
and comparison of the health costs from varied 
disease end points that can result from various 
pollutants. As a measure of equivalent years of 
life lost (YLL) due to illness or disease, DALY 
loss quantifies overall disease costs (impacts) 
due to both mortality and morbidity. DALY 
losses include YLL due to premature mortality 
and equivalent YLL due to reduced health or 
disability (YLD). For each disease, the DALYs 
lost per incidence are calculated as follows:
  DALYdisease = YLLdisease + YLDdisease.  [1]
The equivalent life-years lost to reduced 
health are weighted from 0 to 1 based on the 
severity of the disease. For example, a 5-year 
illness that reduces quality of life to 4/5 that 
of a healthy year is valued at 1 DALY lost.
Several authors have determined the 
DALYs lost per incidence of specific dis-
eases using the preeminent work of Murray 
and Lopez (1996a, 1996b) [Huijbregts et al. 
2005; Lvovsky et al. 2000; World Health 
Organization (WHO) 2009]. Multiplying 
disease incidence by a “DALY factor” yields 
total DALYs lost per disease incidence:
DALYs = (∂DALYs/∂disease incidence)  
 ×  disease incidence.   [2]
Equation 2 uses a partial derivative in 
recog  nition that DALY losses are incremen-
tally affected by causes other than disease. The 
total burden of disease in a community can be 
calculated as the aggregate, across all diseases, 
of DALY factors multiplied by disease inci-
dence rates.
Our analysis used two approaches to cal-
culate DALY losses from estimated exposure 
concentrations. For criteria pollutants [ozone, 
nitrogen dioxide (NO2), particulate matter 
≤ 2.5 μm in aerodynamic diameter (PM2.5), 
sulfur dioxide (SO2), and carbon monoxide 
(CO)] we used an intake–incidence–DALY 
(IND) method that uses epidemiology-based 
C-R functions to quantify disease incidence 
rates; these are combined with estimates of 
DALY losses per disease incidence reported 
in the literature. For non  criteria pollutants we 
used an intake–DALY (ID) approach using 
the work of Huijbregts et al. (2005) to calcu-
late the health impact associated with intake 
of non  criteria pollutants based on animal 
toxicity literature. The IND approach is pre-
ferred because it does not require interspecies 
extrapolations, which generally involve larger 
uncertainties than the epidemiologically based 
C-R functions. However, the IND approach 
can be used only for pollutants with informa-
tion on C-R functions in humans. Ozone was 
the only pollutant for which both the IND 
and ID approaches could be applied.
Although the disease incidence relation-
ships in the IND and ID approaches are 
accepted health impact models, they are 
never  theless simplifications of populationwide 
responses to chronic inhalation exposure. Our 
approaches use linear (i.e., IND) and nearly 
linear (i.e., ID) disease incidence models 
without effect thresholds. For these types of 
disease incidence models, only the mean of the 
concentration distribution is needed to esti-
mate population impact. Existence of a thresh-
old concentration for disease incidence, or a 
strongly non  linear disease-to-intake response, 
would necessitate accurate determination of 
the shape of the population intake distribu-
tion. A discussion of the impact of threshold 
effects on our DALY loss estimates is included 
in the “Discussion.” The potential impacts of 
non  linear response functions are beyond the 
scope of the present study.
The IND approach. The first step of the 
IND method comprises the application of C-R 
functions to determine disease incidence. For 
almost all of the disease outcomes, the C-R 
function follows the formula:
  ΔIncidence =  
    – {y0 × [exp(–βΔCexposure) – 1]}  
   × population,  [3]
where y0 is the baseline prevalence of illness 
per year, β is the coefficient of the concentra-
tion change, Cexposure is the exposure-related 
concentration, and population is the number 
Pollutant Concentration
1,1,2,2-Tetrachloroethane 0.42
1,1,2-Trichloroethane 0.46
1,1-Dichloroethene 1.2
1,2-Dibromoethane 0.14
1,2-Dichloroethane 0.34
1,3-Butadiene 0.46
1,4-Dichlorobenzene 50
2-Butoxyethanol 2.6
2-Ethylhexanol 3.7
2-Ethoxyethanol 0.43
2-Methoxyethanol 0.12
Acetaldehyde 22
Acrolein 2.3
Acrylonitrile 0.27
Ammonia 28
Arsenic 9.8 × 10–4
Atrazine 5.9 × 10–4
Benzaldehyde 2.5
Benzene 2.5
Benzo[a]pyrene 9.1 × 10–5
Benzyl chloride 0.5
Beryllium 1.6 × 10–6
Bis(2-ethylhexyl) phthalate 0.14
Bromodichloromethane 0.49
Bromoform 0.39
Cadmium 2.6 × 10–3
Carbon disulfide 0.34
CO 810
Carbon tetrachloride 0.68
Chlorobenzene 0.68
Chloroethane 0.26
Chloroform 1.5
Chloromethane 1.8
Chromium 2.2 × 10–3
Crotonaldehyde 4.7
Pollutant Concentration
Cyclohexane 5.2
Di(2-ethylhexyl) adipate 1.6 × 10–2
Dibenzo[a,c+a,h]anthracene 1.4 × 10–5
Dibromochloromethane 0.44
d-Limonine 23
Ethanol 860
Ethylbenzene 3.9
Formaldehyde 69
Hexachlorobutadiene 1.7
Hexane 7.3
Isopropylbenzene 0.4
Manganese 3.3 × 10–3
Methyl ethyl ketone 7.4
Mercury 1.6 × 10–4
Methyl methacrylate 0.27
Methylene chloride 8.2
Methyl isobutyl ketone 1.2
Methyl tert-butyl ether 12
Naphthalene 1.2
NO2 13.1
o-Phenylphenol 0.13
Ozone 17.2
Pentachlorophenol 2.9 × 10–3
PM2.5 15.9
Styrene 5.9
SO2 2.9
Tetrachloroethene 1.7
Tetrahydrofuran 15
Toluene 2.3
Trichloroethene 0.16
Vinyl chloride 1.7
Xylene, o 8.2
Xylene, m/p 9.7
Xylenes 7.4
Table 1. Pollutants included in analysis and assumed population-average concentrations (µg/m3).
Abbreviations: CO, carbon monoxide; NO2, nitrogen dioxide; PM2.5, particulate matter ≤ 2.5 μm in aerodynamic diameter; 
SO2, sulfur dioxide. The data are for pollutants identified by Logue et al. (2011) that had sufficient toxicological and 
epidemio  logical data to calculate their health impact. Logue et al.
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of persons exposed. For each pollutant and 
outcome, y0 and β vary. Respiratory illness due 
to long-term NO2 intake requires a slightly 
different C-R functional form but still relies 
on a β with specified uncertainty.
When aggregating C-R functions and 
DALY factors, we tried to include all of the 
diseases with available established relationships 
between concentrations and disease incidence. 
We did not include diseases/outcomes that 
were negligible compared with the other 
diseases included. The health end points 
selected and DALY loss per incidence of 
disease are summarized in Table 2.
Chronic PM2.5 exposure affects both the 
respiratory and cardiovascular systems. The 
three outcomes that we included were all-
cause mortality, chronic bronchitis, and stroke. 
Pope et al. (2002) predicted incidence rates 
of all-cause mortality and the average YLL per 
unit increase in PM2.5 (Pope et al. 2009); we 
divided the former by the latter to get DALYs 
lost per incidence. The 95th percentile range 
of the DALYs lost per death was set to repre-
sent the span of values seen in the literature 
(Lvovsky et al. 2000; Pope et al. 2009). Recent 
studies have shown that chronic PM2.5 expo-
sure can lead to heart disease and thickening 
of arterial walls (Künzli et al. 2004). The total 
impact of PM2.5 on cardiovascular health is 
not known. However, recent work by Miller 
et al. (2007) has shown associations between 
chronic PM2.5 and stroke, an outcome of heart 
disease, in women. The end point of non  fatal 
stroke was included in the analysis using the 
hazard ratios derived by Miller et al. (2007) 
for both men and women. This is likely an 
underestimation of the total impact of PM2.5 
on heart disease. The DALYs lost per non  fatal 
stroke incidence were taken from Brook et al. 
(2010). The incidence of stroke predicted was 
split among 0, 1, and > 1 complications, and 
the percentage of stroke that resulted in death 
was determined based on the findings of Brook 
et al. (2010). Burnett et al. (1999) developed 
a C-R function for hospital admissions associ-
ated with long-term PM2.5 exposure. However, 
because the impact was negligible compared 
with the impact of mortality, chronic bron-
chitis, and stroke, we did not include this out-
come. There is evidence that PM2.5 exposure is 
associated with other health outcomes, includ-
ing diabetes and reduced lung function; how-
ever, these findings are relatively new and have 
not been included in this work.
For CO and SO2, the only outcomes rele-
vant to chronic exposure appear to be hospital 
admissions. Chronic ozone and NO2 exposure 
have been associated with early death and respi-
ratory illness, respectively. The input parameters 
into the C-R functions for these outcomes are 
the same as those used in the U.S. EPA cost–
benefit analysis of the Clean Air Act (U.S. EPA 
1999). For hospital admission and respiratory 
illness, we used the DALY loss/incidence values 
available in the literature. For ozone mortality, 
as with PM2.5, it is unclear how much life is lost 
because of early death. Values in the literature 
range from a few weeks to 10 years; we chose 
a large range of values to represent this uncer-
tainty (Levy et al. 2001; Lvovsky et al. 2000).
The C-R functions are formulated to cal-
culate the increment of disease incidence per 
increment of exposure concentration, not 
total disease incidence for a given exposure 
concentration. According to population-
weighted demographics (Klepeis et al. 2001; 
U.S. Census Bureau 2010), summarized in 
Table 3, the “average” American spends 70% 
of the time in residences. The chronic expo-
sure-relevant concentration contributed from 
indoor exposure was therefore set to 70% of 
the indoor concentration:
 Δ Cexposure = 0.7C indoors.  [4]
Incidence rates were combined with DALY 
factors to calculate total health impacts by pol-
lutant (Equation 2). A Monte Carlo approach 
was used to calculate impacts by pollutant by 
sampling with replacement from the avail-
able distributions of DALY factors and β. We 
assumed that all DALY factor distributions are 
log-normal.
The ID approach. The ID approach 
extrapolated directly from indoor concentra-
tions to total DALYs lost due to intake of 
specific pollutants. From this standpoint, it is 
convenient to rewrite Equation 2 as follows:
DALYs = (∂DALY/∂disease incidence)  
  × (∂disease incidence/∂intake)  
  × intake,    [5]
where intake is the mass of pollutant that an 
individual inhales over a given time frame. 
Table 2. Criteria pollutant C-R function outcomes and DALYs lost per incidence.
Pollutant Outcome β-Coefficient (95% CI)  y0 DALYs lost per incidence (95% CI)
PM2.5 Total mortality  
(Pope et al. 2002)
0.058 (0.002, 0.010) 7.4 × 10–3 1.4 (0.14, 14) (Pope 2007;  
Pope et al. 2002, 2009)
Chronic bronchitis  
(Abbey et al. 1995)
0.091 (0.078, 0.105) 0.4 × 10–3 1.2 (0.12, 12) (Lvovsky et al. 2000; 
Melse et al. 2010)
Non  fatal stroke  
(Brook et al. 2010)
0.025 (0.002, 0.048) 0.2 × 10–3 0 complications: 9.5 (9.25, 9.75)
1 complication: 11.7 (11.1, 12.4)
> 1 complication: 13.1 (12.2, 14.0) 
(Hong et al. 2010)
CO Hospital admissions 
(Burnett et al. 1999)
4 × 10–4 (Lvovsky et al. 2000)
Asthma 0.033 (0.016, 0.050) 1.8 × 10–3
Lung disease 0.025 (0.000, 0.057) 2.1 × 10–3
Dysrhythmias 0.058 (0.012, 0.102) 2.4 × 10–3
Heart failure 0.034 (0.002, 0.066) 3.4 × 10–3
NO2 Hospital admissions 
(Burnett et al. 1999)
4 × 10–4 (Lvovsky et al. 2000)
Respiratory issues 0.004 (0.000, 0.008) 9.5 × 10–3
Congestive heart failure 0.003 (0.001, 0.004) 3.4 × 10–3
Ischemic heart disease 0.003 (0.002, 0.004) 8.0 × 10–3
Respiratory illness, 
indicated by symptoms 
(Hasselblad et al. 1992)
0.028 (0.002, 0.053) N/A 4 × 10–4 (Lvovsky et al. 2000)
Ozone Mortality (Jerrett et al. 
2010; Samet et al. 1997)
0.001 (0.000, 0.002) 7.7 × 10–3 1.0 (0.1, 10) (Levy et al. 2001; 
Lvovsky et al. 2000)
Hospital admissions 
(Burnett et al. 1999)
4 × 10–4 (Lvovsky et al. 2000)
Asthma 0.003 (0.001, 0.004) 1.8 × 10–3
Lung disease 0.003 (0.001, 0.005) 2.1 × 10–3
Respiratory infection 0.002 (0.001, 0.003) 5.8 × 10–3
Dysrhythmias 0.002 (0.000, 0.004) 2.4 × 10–3
SO2 Hospital admissions 
(Burnett et al. 1999)
0.002 (0.000, 0.003) 8.0 × 10–3 4 × 10–4 (Lvovsky et al. 2000)
N/A, not applicable. y0 is the baseline prevalence of illness per year, and β is the coefficient of the concentration change 
used for inputs into Equation 3.
Table 3. Residential occupancy characteristics.
Age (years)
Percent of 
population
Cancer  
ADAF
Percent of day  
spent at home
Air intake 
 (m3/day)
≤ 2 3 10 75 7
2–16 19 3 75 13
≥ 16 78 1 69 15
Population average — 1.6 70 14.4
The percentage of the population in each of these age groups was determined from the U.S. Census Bureau (2010). The 
percentage of time each age groups spends at home was determined from the National Human Activity Pattern Study 
(Klepeis et al. 2001). The age-dependent inhalation rate was taken from U.S. EPA (2009).Chronic health impact of air pollutants in residences
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Huijbregts et al. (2005) computed expected 
ranges of human impact for cancer and non-
cancer chronic effects of 1,192 substances, 
applying equal weightings for a year lost, 
independent of age (i.e., zero discounting). 
Using the values determined by Huijbregts 
et al. (2005), the DALYs lost for 1 year of 
breathing pollutant i is calculated using the 
following equations:
DALYsi = (∂DALY/∂intake) × intake,  [6]
DALYsi =  
  Ci × V × [(∂DALYcancer/∂intake)i  
  × ADAF + (∂DALYnoncancer/∂intake)i],  [7]
where ∂DALY/∂intakei are the cancer and 
non  cancer mass intake-based DALY factors, 
Ci is the indoor concentration, V is volume 
of air breathed in the residence each year, and 
ADAF is the age-dependent adjustment factor 
for cancer exposure as described below.
The age at which carcinogens are inhaled 
has an appreciable effect on total toxicity, 
and the U.S. EPA has developed ADAFs to 
calculate cancer health impact as a function 
of exposure age (U.S. EPA 2005). To align 
with U.S. EPA-recommended ADAFs, we 
considered three age groups: < 2, 2–16, 
and > 16 years of age (U.S. EPA 2005). A 
population-weighted average annual air 
intake volume and ADAF were calculated 
by combining age distribution of the U.S. 
population, age-specific inhalation rates, and 
time spent at home (Table 3).
Huijbregts et al. (2005) presented, for 
each chemical, both a central estimate (50th 
percentile value) and the estimated uncer-
tainty of the DALY losses per mass intake 
of pollutant; uncertainty was assumed to 
be log-normal, characterized by a factor, ki, 
  calculated as follows:
ki = (97.5th percentile/2.5th percentile)0.5,   
    [8]
which includes the aggregated uncertainty 
of the rate of disease incidence as well as the 
uncertainty in the DALY losses per incidence 
of disease. We used a Monte Carlo approach 
to sample with replacement from uncertainty 
distributions of DALY factors derived from 
the central estimate of the DALY factor and 
the ki value, to determine the central estimate 
and 95% confidence interval (CI) for com-
bined cancer and non  cancer DALY losses for 
each pollutant. A Monte Carlo approach was 
also used to determine the total DALYs lost 
from all of the pollutants analyzed using the 
IND and ID methods.
Despite the availability of a DALY factor 
for bromomethane, DALY-based impacts are 
not presented for this compound because the 
limited available concentration data (New 
York State Department of Health 2006) 
appear more indicative of a local outdoor 
source than of general conditions in U.S. 
homes (Logue et al. 2011).
Radon, SHS, and acute CO poisoning 
deaths. The population-average DALYs lost to 
radon, SHS, and acute CO poisoning deaths 
were determined based on estimates of disease 
incidence from the literature. We included 
DALY loss estimates for these pollutants for 
two reasons: a) to compare health impacts 
calculated for a subset of SHS pollutants using 
the IND and ID methodologies to indepen-
dent estimates of overall DALY losses associ-
ated with SHS exposure (as described below), 
and b) to compare estimated IAP-associated 
DALY losses calculated in the present study 
with estimates for these three established 
indoor health hazards.
To estimate the health impact from radon, 
SHS, and acute CO, we used Equation 2 with 
disease incidence estimates from the literature, 
summarized in Table 4. For radon and acute 
CO poisoning, only the end point of prema-
ture death was used to estimate DALY losses. 
The DALYs lost per incidence of various SHS 
outcomes and per early mortality due to acute 
CO poisoning and radon were taken from the 
literature and are also summarized in Table 4.
Comparison with DALY losses estimated 
by other methods. Results from this study were 
compared with three other estimates of popu-
lationwide DALY losses for the United States. 
Although our study used an impact assess-
ment approach, the studies used for compari-
son are cumulative risk assessment (CRA) and 
burden of disease studies (Ezzati and Lopez 
2004; McKenna et al. 2005; WHO 2009). 
The burden of disease studies used available 
statistics to determine the disease incidence rate 
as a function of age, sex, and geographical loca-
tion. A DALY value was then assigned based 
on YLL and disability incurred. The CRA stud-
ies determined the fraction of disease or death 
attributable to a specific risk factor based on 
epidemiological studies of specific populations. 
This is similar to, but far more complex than, 
our method of estimating health impacts due to 
SHS and radon. If the disease rate and DALY 
factors were accurate, and if we used the same 
discount ratings and time weightings for the 
age at which years of life are lost, both methods 
should estimate the same number of DALYs 
lost associated with a specific risk factor. Indoor 
air, independent of the impact of household use 
of solid fuels, had not been studied in a CRA 
analysis thus far. We compared results from our 
methodology with CRA results with the caveat 
that the methods are far from equivalent and 
the comparison should be seen only as a point 
of reference. The comparison also provides a 
useful tool for bounding uncertainties for our 
impact assessment method.
The WHO compiled disease incidence data 
for all communicable and non  communicable 
diseases and injuries to determine the total 
number of DALYs lost per year for 192 coun-
tries (WHO 2009). McKenna et al. (2005) 
aggregated U.S. mortality and morbidity data 
to determine the top 20 causes of DALY losses 
for men and women in 1996. Ezzati and Lopez 
(2004) estimated the total DALYs lost due 
to smoking and tobacco use in industrialized 
nations by determining the impact of dis-
ease beyond what would be expected in non-
smoking homes. The total DALY losses that we 
estimated for all IAPs analyzed with the IND 
and ID methods were compared with estimates 
from these studies to discern whether the full 
CI of the aggregate IAP impact of indoor resi-
dential air is plausible. Additionally, we used 
our IND and ID methodology to calculate 
health impact for a suite of measured SHS 
components, and we compared the aggregate 
CI of the DALYs lost for these components 
with CRA-derived DALY estimates.
SHS is a complex mixture of chemi-
cals. Nazaroff and Singer (2004) estimated 
increases in specific volatile organic compound 
concentrations (1,3-butadiene, 2-butanone, 
Table 4. Health outcomes attributable to SHS, radon, and acute CO poisoning in the United States and the 
DALYs lost per incidence of each health outcome.
Outcome Annual U.S. excess incidence DALYs lost per incidence
SHS
Asthma episodes 202,300 (CalEPA 2005) 40/1,000 cases (Lvovsky et al. 2000)
Otitis media visits 790,000 (CalEPA 2005) 22/1,000 cases (de Hollander et al. 1999)
Sudden infant death syndrome 430 (CalEPA 2005) 78 (current U.S. life expectancy)/case 
(Xu et al. 2010)
Cardiac death 46,000 (95% CI: 22,700, 69,600)  
(CalEPA 2005)
1/case (de Hollander et al. 1999)
Lung cancer death 3,400 (CalEPA 2005) 14/case (de Hollander et al. 1999; 
Melse et al. 2010)
Radon lung cancer deaths
Smokers 18,000 (95% CI: 5,600, 58,000)  
(U.S. EPA 2003)
14/case (de Hollander et al. 1999; 
Melse et al. 2010)
Non  smokers 3,000 (95% CI: 950, 96,000)  
(U.S. EPA 2003)
14/case (de Hollander et al. 1999; 
Melse et al. 2010)
CO acute poisoning deaths 1.53 deaths per million persons  
(95% CI: 1.47, 1.59) (Centers for 
Disease Control and Prevention 2007)
32 (Xu et al. 2010)Logue et al.
220  v o l u m e  120 | n u m b e r 2 | February 2012  •  Environmental Health Perspectives
acetaldehyde, acetonitrile, acrolein, acrylo-
nitrile, benzene, ethyl benzene, formaldehyde, 
naphthalene, phenol, styrene, toluene, and 
xylenes) expected for average smoking activ-
ity. Simons et al. (2007) found that homes 
with smokers had PM2.5 concentrations that 
averaged 16 μg/m3 higher than those in the 
homes of non  smokers. We applied the IND 
and ID modeling frameworks established here 
to determine the additional DALYs lost due 
to living in a household that had indoor con-
centrations elevated by the specified levels. We 
used the Monte Carlo sampling to determine 
an aggregate CI for the DALYs lost due to 
exposure to this chemical mixture.
Results
Figure 1 shows the estimated number 
of DALYs lost due to indoor inhalation 
intake of HAPs and ozone based on the ID 
approach. Formaldehyde and acrolein had 
the largest estimated number of DALYs lost, 
46 (95% CI: 0.2, 14,000) and 47 (95% CI: 
2.4, 1,050), respectively, higher than the 
upper bound of the CI for all but two other 
pollutants, ozone and acetaldehyde. Of the 65 
pollutants compared using the ID method, 
only 15 had 95% CIs that overlapped with 
the 95% CI for formaldehyde.
Figure 2 plots disease incidence and 
DALYs lost using the IND method for chronic 
exposure to criteria pollutants. The estimated 
DALYs lost because of incidences of stroke, 
chronic bronchitis, and premature death due 
to PM2.5 contributed substantially to annual 
health impacts. Mortality due to ozone is also a 
significant contributor to the total DALYs lost. 
The estimated number of DALY losses associ-
ated with hospitalization was relatively low for 
each pollutant. NO2 is potentially a significant 
acute health hazard, but we did not consider 
acute effects in this analysis. Non  lethal chronic 
exposure to CO and SO2 are not substantial 
contributors to DALYs lost from the outcomes 
we evaluated. There is concern that indoor con-
centrations of CO may have an adverse effect 
on certain susceptible populations (U.S. EPA 
2010); however, the current empirical evidence 
is insufficient to reliably quantify the health 
impact from chronic CO exposure.
Figure 3 shows the estimated DALYs lost 
from exposure to the 12 analyzed IAPs with the 
highest DALY losses per year per 100,000 per-
sons. Figure 3 also shows estimates of DALYs 
lost per 100,000 persons per year attributed 
to SHS [51 (95% CI: 42, 60)], acute CO 
deaths [4.9 (95% CI: 4.7, 5.1)], and radon 
exposure for smokers [79 (95% CI: 25, 255)] 
and non  smokers [13 (95% CI: 4, 42)]. For 
smokers, we overestimated the DALY losses 
attributable to radon per se because a portion 
of the DALY losses for smokers exposed to 
radon would result solely from smoking. For 
ozone, the IND and ID approaches estimated 
annual DALY losses per 100,000 persons of 
6.7 (95% CI: 0.3, 160) and 2.3 (95% CI: 0.2, 
26), respectively. There is substantial overlap in 
the CIs for both approaches, although the IND 
CI is smaller. These results suggest that PM2.5, 
acrolein, formaldehyde, radon, and SHS are 
the most harmful non  biological air pollutants 
in residences on a population basis. In addi-
tion, we calculated that intake of the subset of 
compounds in SHS noted above would cause 
an annual loss of 1,000 DALYs (95% CI: 300, 
14,000) per 100,000 residents in households 
with SHS, and a population-averaged annual 
loss of 110 DALYs (95% CI: 40, 1,600) per 
100,000 residents in all U.S. households.
Our analysis yielded a central estimate for 
the DALYs lost due to all IAPs analyzed using 
the IND and ID methods of 1,100 DALYs per 
100,000 persons (95% CI: 400, 13,000) per 
year. For 80% of the Monte Carlo samples, 
indoor PM2.5 was associated with the largest 
number of DALY losses, whereas acrolein and 
formaldehyde were the dominant contributors 
for 16% and 4% of the samples, respectively, 
and another IAP was the dominant contribu-
tor other than these three in < 0.25% of the 
Figure 1. DALY losses associated with intake of indoor air (A), and mean chronic exposure concentrations 
(B), calculated with the ID model. The dots in A represent the central estimate of the DALYs lost, and the 
whiskers indicate the 95% CI.
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Figure 2. Annual DALYs lost (A) and incidence of 
disease (B; estimated by C-R functions) due to cri-
teria air pollutant intake in residences, using the 
IND approach. 
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Monte Carlo samples. For 90% of the samples, 
acrolein, formaldehyde, and PM2.5 contributed 
> 80% of the total DALYs lost. This reinforces 
the finding that these three pollutants account 
for most chronic health effects associated with 
indoor air in non  smoking homes.
Discussion
Although there is large uncertainty in the 
number of DALY losses estimated for each 
pollutant by the IND and ID models, several 
clear findings emerge. Our analysis demon-
strates that in most U.S. residences PM2.5, 
acrolein, and formaldehyde dominate health 
impacts due to chronic exposures to non-
biological air pollutants. The DALY losses 
from these three pollutants appear to be 
much larger than the DALY losses due to CO 
deaths from acute poisoning in homes. SHS 
and radon are also significant contributors to 
populationwide DALY losses, but these expo-
sures occur in a smaller fraction of homes.
Formaldehyde is primarily emitted from 
materials throughout the home. Similarly, 
acrolein is also emitted from such materials; 
however, cooking is also a potentially sig-
nificant indoor source (Seaman et al. 2007). 
PM2.5 concentrations indoors, unlike acrolein 
and formaldehyde, are due to both indoor and 
outdoor sources, and outdoor concentrations 
may exceed indoor levels in many locations 
(Weisel et al. 2005).
Our analysis yielded a central estimate of 
1,100 DALY losses per 100,000 persons (95% 
CI: 400, 13,000) per year for IAPs, excluding 
radon and SHS. For the United States overall, 
WHO (2009) estimated a total burden of 7,700 
DALY losses per year per 100,000 persons for 
all non  communicable, non  psychiatric diseases 
combined. McKenna et al. (2005) identified 
the top 20 diseases that drive the health burden 
in the United States. Of those top 20 diseases, 
those with an indoor-air connection account 
for the loss of 3,000 DALYs per 100,000 per-
sons per year (McKenna et al. 2005). Ezzati 
and Lopez (2004) estimated that the popula-
tion-average burden of both firsthand (smokers) 
and secondhand tobacco smoke in industrial-
ized nations is 12% of the annual DALYs lost, 
which we assume would represent 1,700 DALY 
losses per 100,000 persons per year, that is, 
12% of the total DALY losses estimated for 
the United States by WHO (2009). Estimated 
DALY losses due to indoor PM2.5, acrolein, and 
formaldehyde combined [1,100 (95% CI: 700, 
13,000)] were substantially greater than DALY 
losses due to the remaining 67 IAPs analyzed 
using the IND and ID methods combined [40 
(95% CI: 10, 70)].
Our estimate of DALYs lost to SHS com-
ponents in the 11% of homes estimated to 
have SHS is of similar magnitude to the mean 
estimate of DALY losses from IAP inhalation 
in non  smoking homes. For the SHS analysis, 
pollutants that contribute the most to DALY 
losses are again PM2.5 and acrolein. Having 
a smoker in a residence, on average, doubles 
the concentrations of these two components 
relative to homes without smokers (Nazaroff 
and Singer 2004; Simons et al. 2007), effec-
tively doubling the DALY loss estimates. The 
complete chemical mixture of SHS should be 
more toxic than the limited subset of com-
ponents examined here, but the DALY loss 
estimate derived from the literature-reported 
health end points due to SHS is in the lower 
bound of the 95% CI. This result suggests that 
the component-based method used in this 
study may tend to overestimate DALY losses 
or that an insufficient number of health end 
points are attributed to SHS.
Both the IND and ID approaches rely on 
no-threshold disease incidence models that are 
linear or effectively linear over the concentra-
tion range of the analysis. The health impacts 
of PM2.5 are broadly thought to be linear at 
low doses (Schwartz et al. 2002). Threshold 
effects may significantly reduce the actual 
health impacts due to formaldehyde (a cancer 
hazard) and acrolein exposure (a non  cancer 
hazard). Although some studies have identified 
genotoxic effects for formaldehyde (Viegas et al. 
2010), others have identified strong thresh-
old effects (Salthammer and Bahadir 2009). 
Various thresholds for exposure to avoid cancer 
have been suggested, ranging from 120 μg/m3 
suggested by the German Federal Institute for 
Risk Assessment and WHO to 12 μg/m3 sug-
gested by Naya and Nakanishi (2005). Given 
the distribution of formaldehyde concentra-
tions determined for residences, threshold 
effect levels of 12 μg/m3 and 120 μg/m3 would 
result in 32% and 87% reductions in predicted 
DALY losses, respectively. A high threshold 
would result in PM2.5 and acrolein being the 
prime indoor pollutants of concern and form-
aldehyde being of lesser importance.
Less information is available on threshold 
levels for acrolein exposure. We determined 
the impact on the DALY loss estimate for a 
threshold equal to the CalEPA non  cancer ref-
erence exposure level (0.35 μg/m3). Given the 
determined distribution of acrolein concen-
trations indoors, this would result in a 20% 
reduction in DALY losses.
Conclusion
Using the methodology established here, we 
estimated that the total annual health impact 
of IAP inhalation in U.S. residences, exclud-
ing radon and SHS, is 1,100 DALY losses 
per 100,000 persons (95% CI: 400, 13,000). 
The upper bound of the range was twice as 
high as the number of DALY losses due to 
all non  communicable, non  psychiatric dis-
eases as estimated by WHO (2009) based on 
disease statistics. The upper bound of the CI 
estimated for the DALYs lost due to exposure 
to a subset of pollutants in SHS using the 
methodology was also implausibly high. The 
total annual DALYs lost due to IAPs is likely 
in the lower half of the calculated range, that 
is, between the central estimate (1,100) and 
lower bound of the 95% CI (400) in DALY 
losses per 100,000 persons.
Because the upper-bound CI for all 
IAP-related DALY losses is too high, the 
upper-bound for CIs of at least some of the 
individual pollutants included must also be 
too high. Because the vast majority of the total 
DALY losses were due to acrolein, PM2.5, and 
formaldehyde, further statistical analysis may 
be able to narrow the currently large CIs for 
impacts from these pollutants.
Figure 3. Estimated population-averaged annual cost, in DALYs lost, of chronic air pollutant inhalation in 
U.S. residences: results for the 12 pollutants with highest median DALY loss estimates. The markers rep-
resent the central estimate, and the whiskers indicate the 95% CI. Squares indicate pollutant DALY losses 
calculated using the ID approach. Circles indicate DALY losses calculated using the IND approach. Radon, 
acute CO deaths, and SHS DALY losses were calculated using disease incidence rates attributed to them 
in the literature.
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